Lung cancer diagnosis typically begins with imaging, moves to a biopsy to confirm cancer cells, and finishes with molecular testing that shapes treatment decisions. The full process, from the first scan to a complete pathology report, often takes several weeks. Here’s what each step involves and what to expect along the way.
Screening Before Symptoms Appear
Most lung cancers are caught after symptoms develop, but annual screening with a low-dose CT scan (LDCT) can detect tumors earlier, when they’re smaller and more treatable. The U.S. Preventive Services Task Force recommends yearly LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and either still smoke or quit within the past 15 years. A pack-year equals smoking one pack (20 cigarettes) per day for one year, so someone who smoked two packs a day for 10 years has a 20 pack-year history.
Screening stops once someone has been smoke-free for 15 years or has a health condition that would rule out surgery if cancer were found. A standard chest X-ray is not recommended for screening because it misses small tumors that LDCT picks up reliably.
Initial Imaging: CT Scans and X-Rays
When lung cancer is suspected, whether from screening, a persistent cough, unexplained weight loss, or chest pain, the first diagnostic step is almost always a CT scan of the chest. A regular chest X-ray might reveal a large mass, but it lacks the resolution to characterize smaller nodules or see how far a tumor extends. CT scans produce detailed cross-sectional images that show the size, shape, and location of a suspicious spot, and they help doctors decide whether a biopsy is needed.
If the CT scan shows something concerning, the next question is whether the abnormality is cancer, and if so, whether it has spread. That’s where PET scans and biopsies come in.
PET Scans for Staging and Spread
A PET scan works differently from a CT scan. Instead of just showing anatomy, it highlights areas of high metabolic activity. Cancer cells burn through glucose much faster than normal cells, so before the scan you receive an injection of a radioactive sugar tracer. Cancer cells absorb more of it, trapping it inside, which makes tumors glow on the scan relative to surrounding tissue.
PET scans are especially valuable for staging, meaning determining how far cancer has spread. A CT scan alone detects clear evidence of metastatic disease in roughly 11 to 36 percent of patients at initial staging. Adding a PET scan reveals hidden distant metastases in an additional 5 to 29 percent of cases that CT missed entirely. The scan is particularly good at identifying cancer that has spread to the adrenal glands, bones, or lymph nodes. Most centers now use combined PET/CT scanners that fuse metabolic and anatomical data into a single image, giving doctors a more complete picture in one appointment.
Biopsy: Confirming the Diagnosis
Imaging can strongly suggest cancer, but a biopsy is required to confirm it. A pathologist needs to examine actual cells under a microscope. There are several ways to obtain tissue, and the method depends on where the tumor is located and how accessible it is.
CT-Guided Needle Biopsy
For tumors near the outer edges of the lung, a radiologist inserts a thin needle through the chest wall while using CT images in real time to guide the needle tip into the nodule. The procedure is done under local anesthesia and typically takes less than an hour. The most common complication is a pneumothorax, a small air leak where the lung partially deflates. This happens in roughly 28 percent of cases, though the vast majority of those resolve on their own. Only about 2.5 percent of patients need a chest tube to reinflate the lung. After the procedure, you’ll have follow-up chest X-rays over the next 24 hours to check for any air leak.
Bronchoscopy and EBUS
For tumors located centrally, near the major airways, doctors use bronchoscopy. A thin, flexible tube with a camera is passed through the mouth or nose and into the airways, allowing the doctor to see the tumor directly and take samples. A more advanced version called endobronchial ultrasound (EBUS) attaches a small ultrasound probe to the tip of the bronchoscope. This lets the doctor see through the airway walls and precisely sample lymph nodes in the space between the lungs (the mediastinum), which is critical for determining whether cancer has spread to nearby nodes. EBUS avoids the need for a surgical incision and is the standard approach for staging the central chest.
Surgical Biopsy
In some cases, when a nodule is hard to reach with a needle or bronchoscope, a surgeon may perform a minimally invasive procedure using small incisions and a camera to remove a tissue sample or the entire nodule. This is less common as a first step but sometimes serves double duty: if the nodule turns out to be cancer, the surgeon may remove it in the same operation.
Pathology Results and Timeline
Once tissue is collected, a pathologist examines it to determine whether cancer cells are present and, if so, what type. The two broad categories are non-small cell lung cancer (NSCLC), which accounts for about 80 to 85 percent of cases, and small cell lung cancer, which is less common but tends to grow faster. Within NSCLC, subtypes like adenocarcinoma and squamous cell carcinoma behave differently and respond to different treatments.
Pathology reports are typically sent to your doctor within 10 days of the biopsy, according to the National Cancer Institute. However, this initial report covers the basic diagnosis. Molecular testing, which analyzes the tumor’s genetic profile, adds additional time.
Molecular and Biomarker Testing
For non-small cell lung cancer, knowing the tumor’s genetic mutations is just as important as knowing the cancer type. Certain genetic changes in the tumor act as targets for specific drugs that can be far more effective than standard chemotherapy. The most commonly tested markers include changes in genes called EGFR, ALK, and ROS1, along with a protein called PD-L1 that indicates how the tumor interacts with the immune system.
Finding one of these markers can fundamentally change your treatment plan. For example, tumors with an EGFR mutation respond to targeted pills rather than traditional IV chemotherapy, and high PD-L1 levels suggest immunotherapy may work well. These genomic abnormalities are considered crucial predictive biomarkers, and identifying them has a demonstrated positive impact on overall survival. Testing is performed on the same tissue sample taken during biopsy, though it requires additional laboratory techniques and can take one to three weeks beyond the initial pathology report.
Liquid Biopsy as a Backup Option
When a traditional tissue biopsy is too risky or doesn’t yield enough material, a blood draw called a liquid biopsy can sometimes fill the gap. Tumors shed tiny fragments of their DNA into the bloodstream, known as circulating tumor DNA. A lab can analyze this DNA to detect the same genetic mutations found through tissue testing.
Liquid biopsy is not a replacement for tissue biopsy, which remains the gold standard. But it serves as a useful backup for patients with advanced-stage disease where reaching the tumor is difficult or dangerous. It’s also increasingly used to monitor how well treatment is working and to detect signs of recurrence without repeated invasive procedures.
Putting It All Together
The complete diagnostic picture comes from layering all of these results. Imaging defines the location and size. PET scans map any spread. Biopsy confirms the cancer type. Molecular testing identifies targetable mutations. Together, these determine the cancer’s stage, which ranges from stage I (a small, localized tumor) to stage IV (cancer that has spread to distant organs), and dictate which treatment approach gives you the best outcome. From the first suspicious scan to a finalized treatment plan, the process commonly spans three to six weeks, depending on how quickly each test can be scheduled and processed.